Zhou G, Qu W, Yang L, Huang A, Gui X
    
    
    BMC Womens Health. 2025; 25(1):89.
  
  
    PMID: 40016720
    
          PMC: 11866700.
    
          DOI: 10.1186/s12905-025-03608-3.
      
 
                                  
  
    Ortega M, Boaru D, De Leon-Oliva D, De Castro-Martinez P, Minaya-Bravo A, Casanova-Martin C
    
    
    Genes (Basel). 2025; 16(2).
  
  
    PMID: 40004457
    
          PMC: 11854833.
    
          DOI: 10.3390/genes16020128.
      
 
                                  
  
    Jablonska K, Kmiecik A, Nowinska K, Piotrowska A, Suchanski J, Ratajczak-Wielgomas K
    
    
    Int J Mol Sci. 2025; 26(4).
  
  
    PMID: 40003884
    
          PMC: 11855718.
    
          DOI: 10.3390/ijms26041416.
      
 
                                  
  
    Papa V, Furci F, Minciullo P, Casciaro M, Allegra A, Gangemi S
    
    
    Curr Issues Mol Biol. 2025; 47(2).
  
  
    PMID: 39996790
    
          PMC: 11854756.
    
          DOI: 10.3390/cimb47020069.
      
 
                                  
  
    Aljadani F, Nughays R, Alharbi G, Almazroy E, Elyas S, Danish H
    
    
    Breast Cancer (Dove Med Press). 2025; 17:171-186.
  
  
    PMID: 39990965
    
          PMC: 11846536.
    
          DOI: 10.2147/BCTT.S505725.
      
 
                              
              
                              
                                      
  Dual-functional probe for sensitive detection of MCF-7 cells and mendelian randomization analysis of MUC1 association with multiple cancers.
  
    Wu Z, Chen Q, Lin Z, Chen Y, Gan X, He Y
    
    
    Sci Rep. 2025; 15(1):6167.
  
  
    PMID: 39979505
    
          PMC: 11842835.
    
          DOI: 10.1038/s41598-025-90575-2.
      
 
                                          
                                                          
  F-fluorodeoxyglucose positron emission tomography-computed tomography for predicting pathological complete response to neoadjuvant chemotherapeutic in breast cancer patients.
  
    Ge C, Shi L, Tan Z
    
    
    Gland Surg. 2025; 14(1):48-59.
  
  
    PMID: 39958895
    
          PMC: 11826249.
    
          DOI: 10.21037/gs-2024-568.
      
 
                                          
                                                          
  Synergistic therapeutic effects of pertuzumab and pyrrolitinib in HER-2-positive breast cancer: modulation of the PI3K/AKT pathway.
  
    Zhu X, Xu Y, Zheng X, Li Y
    
    
    Am J Cancer Res. 2025; 15(1):141-152.
  
  
    PMID: 39949924
    
          PMC: 11815364.
    
          DOI: 10.62347/COSC7070.
      
 
                                          
                                                          
  Intratumoral injection of two dosage forms of paclitaxel nanoparticles combined with photothermal therapy for breast cancer.
  
    Sun L, Zuo C, Ma B, Liu X, Guo Y, Wang X
    
    
    Chin Herb Med. 2025; 17(1):156-165.
  
  
    PMID: 39949814
    
          PMC: 11814247.
    
          DOI: 10.1016/j.chmed.2024.06.001.
      
 
                                          
                                                          
  An update on cancer stem cell survival pathways involved in chemoresistance in triple-negative breast cancer.
  
    Jan A, Sofi S, Jan N, Mir M
    
    
    Future Oncol. 2025; 21(6):715-735.
  
  
    PMID: 39936282
    
          PMC: 11881842.
    
          DOI: 10.1080/14796694.2025.2461443.
      
 
                                          
                                                          
  Advances in Ultrasound-Targeted Microbubble Destruction (UTMD) for Breast Cancer Therapy.
  
    Wu Y, Liu Y, Wu H, Tong M, Du L, Ren S
    
    
    Int J Nanomedicine. 2025; 20:1425-1442.
  
  
    PMID: 39925678
    
          PMC: 11804227.
    
          DOI: 10.2147/IJN.S504363.
      
 
                                          
                                                          
  Parishin B blocking TRIB3-AKT1 interaction inhibits breast cancer lung metastasis.
  
    Cheng X, Sun J, Chen S, Wang N, Tang W, Xia Z
    
    
    Front Pharmacol. 2025; 15:1517708.
  
  
    PMID: 39881875
    
          PMC: 11775015.
    
          DOI: 10.3389/fphar.2024.1517708.
      
 
                                          
                                                          
  From Pioneering Discoveries to Innovative Therapies: A Journey Through the History and Advancements of Nanoparticles in Breast Cancer Treatment.
  
    Basingab F, Alshahrani O, Alansari I, Almarghalani N, Alshelali N, Alsaiary A
    
    
    Breast Cancer (Dove Med Press). 2025; 17:27-51.
  
  
    PMID: 39867813
    
          PMC: 11761866.
    
          DOI: 10.2147/BCTT.S501448.
      
 
                                          
                                                          
  The Anticancer Perspective of Tangeretin: A Small Review.
  
    Xu Y, Yan X, Zhuang J, Hao H
    
    
    Molecules. 2025; 30(2).
  
  
    PMID: 39860170
    
          PMC: 11767889.
    
          DOI: 10.3390/molecules30020300.
      
 
                                          
                                                          
  Predictive modeling of breast cancer-related lymphedema using machine learning algorithms.
  
    Sun Y, Xia X, Liu X
    
    
    Gland Surg. 2025; 13(12):2243-2252.
  
  
    PMID: 39822356
    
          PMC: 11733644.
    
          DOI: 10.21037/gs-24-252.
      
 
                                          
                                                          
  Effect of Strength Training on Body Composition, Volumetrics and Strength in Female Breast Cancer Survivors.
  
    Pardo-Hernandez R, Fernandez-Solana J, Gonzalez-Bernal J, Romero-Perez E, Horta-Gim M, Riojas Pesqueira L
    
    
    Healthcare (Basel). 2025; 13(1.
  
  
    PMID: 39791636
    
          PMC: 11719464.
    
          DOI: 10.3390/healthcare13010029.
      
 
                                          
                                                          
  Hypoxic BMSC-derived exosomal miR-210-3p promotes progression of triple-negative breast cancer cells via NFIX-Wnt/β-catenin signaling axis.
  
    Wang M, Zheng Y, Hao Q, Mao G, Dai Z, Zhai Z
    
    
    J Transl Med. 2025; 23(1):39.
  
  
    PMID: 39789572
    
          PMC: 11720919.
    
          DOI: 10.1186/s12967-024-05947-5.
      
 
                                          
                                                          
  Effect of low-dose radiation pre-irradiation on postoperative local chest wall recurrence of breast cancer-A retrospective study.
  
    Zeng R, Wang H, Cai X, Lin J, Li P, Zeng S
    
    
    PeerJ. 2025; 13:e18717.
  
  
    PMID: 39763698
    
          PMC: 11700491.
    
          DOI: 10.7717/peerj.18717.
      
 
                                          
                                                          
  SLC35A2 is a novel prognostic biomarker and promotes cell proliferation and metastasis via Wnt/β-catenin/EMT signaling pathway in breast cancer.
  
    Yan R, Chen T
    
    
    Sci Rep. 2025; 15(1):130.
  
  
    PMID: 39748019
    
          PMC: 11695858.
    
          DOI: 10.1038/s41598-024-84584-w.
      
 
                                          
                                                          
  Asparagine endopeptidase regulates lysosome homeostasis via modulating endomembrane phosphoinositide composition.
  
    Yao L, Zi G, He M, Xu Y, Wang L, Peng B
    
    
    Cell Death Dis. 2025; 15(12):883.
  
  
    PMID: 39743643
    
          PMC: 11693757.
    
          DOI: 10.1038/s41419-024-07187-3.